Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab versus standard of care in previously treated aggressive B-cell non-Hodgkin lymphoma
NL-OMON60879Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in mature B-cell lymphoma comparing Odronextamab monotherapy with Standard of care (2 arms). Primary endpoint: Event-free survival. Started Jun 2023; status: completed.
02
Drugs
odronextamab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON60879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60879.